Intraperitoneal Chemotherapy Guided by the Detection of DNA in Peritoneal Lavage Fluid in Patients With Gastric Cancer
Summary
Peritoneal metastasis is a major pattern of gastric cancer recurrence and predicts poor prognosis. In our previous study, we developed a next-generation sequencing technology to detect minimal residual cancer cells in peritoneal lavage fluid with a personalized assay profiling tumor-specific mutations in patients with gastric cancer. With this technology, we predicted all the cases that developed peritoneal metastasis in patients with pT4 disease with 100% sensitivity and 91% specificity. Based on this result, a prospective phase 2 clinical trial is designed to evaluate the efficacy of adjuvant intraperitoneal chemotherapy in patients with positive cancer cell DNA detected in peritoneal lavage fluid by our personalized tumor-specific mutation profiling assay.
Timeline
- Start
- 2022-06-28
- Primary completion
- 2024-06-20
- Completion
- 2024-06-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 25 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 80 mg | — |
| Subject | Paclitaxel | Small molecule | 100 mg | — |
| Subject | aldesleukin | Protein / enzyme biologic | 2e+06 iu | — |
| Subject | fluorouracil | Small molecule | 1000 mg/m2 | — |
| Background | Oxaliplatin | Small molecule | 85 mg/m2 | — |
| Background | S-1 | Small molecule | 40 mg | — |
| Background | S-1 | Small molecule | 50 mg | — |
| Background | S-1 | Small molecule | 60 mg | — |